Table of Contents
Angiotensin receptor blockers (ARBs) are a class of medications commonly prescribed for conditions such as hypertension and heart failure. While effective, their use during pregnancy requires careful consideration due to potential risks to the developing fetus.
Understanding ARBs and Pregnancy Risks
ARBs work by blocking the effects of angiotensin II, a substance that narrows blood vessels. During pregnancy, especially in the second and third trimesters, these medications can interfere with fetal renal development, leading to complications such as oligohydramnios, renal failure, and even fetal death.
Guidelines for Pharmacists
- Screen for pregnancy: Always verify pregnancy status before dispensing ARBs.
- Counsel patients: Inform women of childbearing age about the potential risks associated with ARB use during pregnancy.
- Recommend alternatives: For pregnant women or those planning pregnancy, suggest safer antihypertensive options such as methyldopa or labetalol.
- Coordinate with healthcare providers: Communicate with prescribers to ensure appropriate medication management during pregnancy.
- Document counseling: Record all discussions regarding medication risks and alternatives.
Managing Discontinuation and Transition
If a patient becomes pregnant while on ARBs, it is essential to consult with the healthcare provider immediately. Discontinuing ARBs early in pregnancy can reduce risks, and alternative medications should be initiated under medical supervision.
Educational Resources
- FDA Pregnancy and Lactation Labeling
- World Health Organization guidelines
- American Society of Health-System Pharmacists
Staying informed and vigilant ensures the safety of both mother and fetus. Pharmacists play a crucial role in counseling and guiding patients through medication choices during pregnancy.